Table 2.

Summary of our patient.

Patient Sex/age	Oncological history	Molecular biology	Treatment	Outcome
M/55	May 2022: Glioblastoma Grade 4. Jan. 2023: Development of abducens palsy and detection of intracranial progression. Feb. 2023 ENM metastases to bone, soft tissue, lymph nodes, lung, and mesentery.	Primary tumor: IDH-1/-2 wild-type, MGMT methylated, TERT promotor wild-type, TP53 wild-type, EGFR amplification Paravertebral metastasis: BRAF wild-type, NTRK 1-3 no translocation, PD-L1 partly highly upregulated.	May 2022: Neurosurgical debulking of primary tumor. June 2022: 75 mg/m2 temozolomide concurrent to 2 Gy x 30 radiation. Aug./Sept.: Temozolomide as adjuvant therapy, six cycles. Feb. 2023: Radiation therapy 4 Gy x 5 against column. March 2023: Lomustine, bevacizumab and vincristine.	Time from diagnosis to death: 11 months. Time from diagnosis to ENM: Nine months Time from ENM to death: Two months.